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SYNOPSIS 
Advances in medical science have led to 
increased life expectancy and increased median 
age in the population. Because the symptoms of 
neurodegenerative diseases generally onset in 
mid- to late-life, a concomitant increase in the 
number of persons afflicted with these 
devastating diseases has occurred. Developing 
therapies for neurodegenerative diseases is of 
the highest priority due to the enormous cost of 
medical care required, as well as for the human 
suffering involved. Although caused by a 
variety of genetic and environmental insults, 
such diseases share commonalities. Many of 
these diseases are proteinopathies-diseases 
caused by misfolded, aggregating proteins. 
Antibodies that can recognize and remove 
misfolded proteins are ideally suited for 
proteinopathy therapeutics. The numerous 
intriguing advances in antibody-based therapies 
for neurodegenerative diseases are discussed in 
this review. 
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IMMUNIZATION THERAPIES FOR 
ALZHEIMER'S DISEASE 
Preclinical experiments with A~ protein 
Alzheimer's disease (AD) affects some 26 
million individuals worldwide, yet the currently 
available drugs treat only the symptoms. Thus, the 
need is urgent for the development of novel 
therapies. Moreover, such therapies should target 
the upstream events involved in causing the 
dementia that characterizes this disorder. 
The primary diagnostic signs in postmortem 
AD brain are plaques that contain AI3 protein 
aggregates and neurofibrillary tangles (NFTs) that 
contain the hyperphosphorylated tau protein. 
Perhaps the most novel therapeutic strategy 
currently under study for AD is the use of 
antibodies (Abs) directed at either or both AI3 and 
tau. Indeed, the results from preclinical work using 
this approach with various mouse AD models have 
been so promising that at least 13 different AI3 
immunotherapy trials are currently in progress, 
enrolling an estimated 9,000 AD patients 
worldwide 1401. 
This line of work began in 1996 with the 
finding by Solomon and colleagues that anti-AI3 
monoclonal Abs can dissolve AI3 aggregates in 
vitro and prevent AI3 monomers from aggregating 
169,701. The finding that startled the field and 
brought AD immunotherapy to the fore was the 
dramatic result of immunizing the PDAPP AD 
mouse model, which as it ages develops plaques 
and memory deficits, with pre-aggregated AI31-42. 
This treatment prevented plaque deposition and 
reduced the number of existing plaques, total AI3 
load, and gliosis 165/. Many groups have since 
extended these findings to a number of other 
mouse AD models and shown that behavioral 
deficits, including learning and memory, can be 
prevented by active immunization with various 
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types of A/3 immunogens and adjuvants. The 
ability of such active immunization protocols to 
reverse established neuropathology and behavioral 
deficits has been variable, however /401. 
Given that animals are heterogeneous in the 
ability to mount a strong immune response, a 
logical alternative to the active immunization 
method is the passive approach, wherein purified 
anti-Af3 polyclonal or monoclonal Abs are 
injected. In fact, studies have shown that passive 
Abs immunotherapy is effective in reducing 
established plaque and A/3 levels, neuritic 
dystrophy, behavioral deficits and, in one case, 
reduced aggregation of phosphorylated tau. The 
latter observation, among others, suggested that tau 
pathology is downstream of A/3 pathology 152/. 
Clinical trials with A/3 
The remarkable results with the transgenic A/3 
mouse models led immediately to several early 
human trials. Despite the worry that anti-A/3 Abs 
might cause autoimmune problems, in 1999 Elan 
and Wyeth 1201 proceeded with a Phase I safety 
trial of 80 patients using the AN 1792 vaccine 
consisting of a synthetic A/31-42 peptide and the QS-
21 saponin adjuvant. Eighty mild to moderate AD 
patients received 4 intramuscular injections of 
peptide + adjuvant, peptide alone, adjuvant alone, 
or placebo over 6 months. No serious adverse 
events were reported. In 2001, a Phase IIa 15-
month double-blind, placebo-controlled trial 
followed involving 372 mild to moderate AD 
patients. This trial was stopped in 2002 after 6% of 
the patients developed aseptic meningoencephalitis 
and leukoencephalopathy. The ANI 792 + adjuvant 
approach was designed to accentuate a cell-
mediated immune response, which is appropriate 
for the elderly who often have a reduced immune 
response. Thus, it may be that the patients 
developing serious clinical side effects produced 
A/3-reactive autoimmune T cells. 
Fortunately, some data are available on the 
efficacy of this immunotherapy trial that was halted 
prematurely. In a subgroup of the 30 Phase II 
patients at one center, improvements in some 
cognitive tests were seen in the 6 patients that 
exhibited the highest Ab titers 126/. In a follow-up 
study 4.6 years later, another subset of vaccine-
treated patients displayed a much-reduced rate of 
functional decline on the Dependence Scale and the 
Disability Assessment for Dementia Scale /78/. Oli 
the other hand, a volumetric MRI study showed 
that, compared with the controls, the Ab responders 
displayed increased loss of brain volume and 
increased ventricular enlargement. These anatomical 
changes did not, however, correspond with the 
enhanced Neuropsychological Test Battery scores 
that the antibody responders achieved over the 
controls 1201. Although these seemingly contra-
dictory findings remain to be explained, the 
cognitive testing results are encouraging, although 
certainly not as dramatic as those obtained in the 
mouse studies. 
In terms of neuropathology, eight patient brains 
from the Phase I trial have been analyzed and 
showed a reduction in A/3 load, with 2.1 % of the 
area of the neuropil covered by amyloid staining in 
the AN1792 group compared with 5.1% in the 
control group, a difference that reached significance 
127/. Despite their lower plaque levels, however, 
all eight vaccinated patients displayed severe 
dementia at the time of death. This result is 
consistent with previous AD findings showing 
little correspondence between plaque load and 
dementia. In fact, individuals with normal 
cognition for their age group can exhibit 
significant plaque loads 151. Such findings 
highlight the need for a better identification of the 
potential drivers of neurotoxicity, the A/3 
oligomers, which can be stained by specific Abs 
122/. Yet another provocative finding from 9 
patients who died between 4 months and 5 years 
after their first immunization is the observation 
that 15 times as many cerebral blood vessels were 
coated with A/3 than controls. These patients also 
had a higher density of cortical microhemorrhages 
and microvascular lesions than did unimmunized 
controls. Unlike most of the immunized patients, 
however, two of the longest survivors had a 
virtually complete absence of plaques as well as 
cerebral amyloid angiopathy /71. The authors 
optimistically interpreted these findings as 
suggesting that the injected Abs mobilize A/3 from 
the plaques, which then exits the brain via the 
cerebral vasculature, causing a transient increase in 
cerebral amyloid angiopathy. 
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At least seven more trials of passive immuno-
therapies for mild to moderate AD are underway. 
The results from a trial of a humanized monoclonal 
Ab (bapineuzimab, AAB-001) that binds the N-
terminus of A/3 indicated that the trial did not meet 
its endpoints for cognitive efficacy. A post hoc 
analysis, however, unadjusted for multiple 
compar:sons found significant cognitive benefits 
(p < .05) in those AD patients who did not carry 
the apolipoprotein E (APOE) e4 allele /64/. As this 
allele is a major risk factor for AD, the results 
suggest that the potentially more severe patho-
genesis in the carriers could not be overcome by 
the immunotherapy. Given the lack of dramatic 
effects, however, this trial did not have the power 
to determine if this monoclonal Ab had real 
cognitive benefits. The possible effect of the 
APOE allele is an important tip for future trials. 
Current Phase III bapineuzimab trials have 
enrolled 4,000 patients. 
Another humanized monoclonal antibody, 
solanezumab (LY2062430) that binds the middle 
of A/3 met safety standards in 52 patients, but 
cognitive scores were not affected. Increased levels 
of several forms of A/3 were detected at high levels 
in sera, however, consistent with the mobilization 
of these peptides. Two large Phase III studies are 
underway, enrolling 2,000 patients. Several new 
trials are also underway using a modified active 
immunization approach /40/. 
Experiments with IVIg antibodies 
An alternative immunotherapy involves intra-
venous immunoglobulin (IVIg). This approach has 
the advantage that the U.S. Food and Drug 
Administration has approved such injections as 
safe for several immune and inflammatory 
diseases. The Ig preparation is manufactured from 
the plasma of healthy subjects. This pooled 
mixture contains anti-A/3 antibodies that can block 
the formation of A/3 oligomers and fibrils, enhance 
the clearance of A/3 from the brain, and protect 
neurons from A/3 toxicity in culture /40/. 
Moreover, in a pilot study, IVIg treatment 
stabilized cognitive loss in five AD patients /14/. 
In another study of 8 AD patients, IVIg was 
administered for 6 months, stopped for 3 months, 
and then resumed for 9 months. The treated 
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patients displayed improvement in mini-mental 
state examination scores at 6 months, declined 
during the washout, and then stabilized for the 
final 9 months /60/. In addition, anti-A/3 Abs were 
found in the CSF, suggesting that they can cross 
the BBB. Several further studies of IVIg therapy 
are now in progress. 
In addition to the clinical trials, a retrospective 
case-control analysis examined the incidence of 
AD and related disorders in people> 65 years old 
who had received IVIg for other indications. Five 
years after the start of the analysis, this group had a 
42% lower risk of AD diagnosis /19/. Thus, both 
epidemiologic and early clinical findings with IVIg 
are encouraging, despite the fact that the anti-A/3 
Abs in the preparation are only a minor component 
of the mixture, and they have not been optimized 
for efficacy. 
Anti-tau immunotherapy 
The second major hallmark of AD, the NFTs 
containing hyper-phosphorylated tau, has only 
recently begun to receive significant attention as an 
immunotherapeutic target. According t6 the 
amyloid hypothesis of AD, tau pathology is 
downstream of misfolded A/3, although a dual 
pathway hypothesis has also received support /68/ .. 
In fact, mutations in tau can cause frontotemporal 
dementia with parkisonsim (FTDP) in the absence 
of amyloid plaques, and NFTs are better correlated 
with dementia in late onset AD than are plaques. 
Moreover, in one AD mouse model, anti-A/3 
immunotherapy cleared NFTs but not hyper-
phosphorylated tau aggregates /52/, which has also 
been seen in human studies. 
The first anti-tau immunotherapy results used a 
mouse model expressing a FTDP tau mutation /3/. 
Immunization with a. tau peptide containing two 
phosphorylated serines associated with NFTs 
resulted in the reduction of insoluble tau and an 
increase in soluble tau. Motor performance on the 
balance beam and rotarod was improved in the 
immunized group, but cognitive tests were not 
informative. Tagged Abs were detected in the 
brains of transgenic but not wild type mice, 
indicating that the Abs can cross the BBB in this 
model. It will be important to test this therapy in a 
true mouse model of AD. As in the A/3 experiments, 
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the choice of the tau preparation used as antigen can 
be critical, as certain immunogens can cause 
pathology in normal mice /63/. A focus on the toxic 
tau oligomers may prove to be the most productive 
approach, as may be true for A13 immunization /32/. 
IMMUNIZATION THERAPIES FOR 
PARKINSON'S DISEASE 
Among the mutations that can cause 
Parkinson's disease (PD), those that have received 
the most attention are in the protein a-synuclein. 
This protein is also found in the Lewy body 
inclusions that are characteristic of the idiopathic, 
non-familial form of the disease. Contemplating 
immunization approaches targeting a-synuclein 
may appear at first to be misguided, as this protein 
is thought to be intracellular, localized primarily in 
presynaptic terminals. The evidence shows that 
under pathological conditions, however, a-synuclein 
oligomers and protofibrils are detectable on the 
plasma membrane /13,15,38/. Moreover, a series of 
recent studies has demonstrated that a mutant a-
synuclein protein can be transferred from cell to 
cell, spreading the disease in the brain in a prion-
like (but non-infectious) manner /1/. Thus, 
circulating Abs may have access to a-synuclein. 
The major immunotherapy work published 
thus far has employed active immunization with 
human a-synuclein for 8 months in a mouse model 
over-expressing human a-synuclein /46/. This 
model displays motor deficits and signs of synaptic 
degeneration that were attenuated by immunization. 
The levels of aggregated human a-synuclein were 
also diminished, and the effects correlated with the 
relative affmity of the Abs generated in the mice. 
The injection of tagged, purified monoclonal, anti-
human a-synuclein Abs resulted in binding to cell 
bodies and synapses in a-synuclein-expressing but 
not in wild type mice. Cathepsin D was up-
regulated in the labeled neurons, suggesting that 
the circulating Abs can recognize the aggregated 
a-synudein and cause its clearance via lysosomal 
activation /46/. 
In a different type of passive immunotherapy 
approach, adoptive transfer, immune cells that 
cross-react with myelin basic protein (MBP) were 
injected in the MPTP mouse model of PD /6/. The 
cells were generated by stimulating donor mice 
with copolymer-l (Cop-I; Copaxone, glatiramer 
acetate) /75/, a random amino acid polymer that 
protects against brain mJury without the 
encephalitis associated with MBP immunization. 
The rationale for the use of these immune cells in 
the PD model is that Cop-l stimulates TH2 cells, a 
T-cell subset that secretes anti-inflammatory 
cytokines, as inflammation is part of the toxic 
neuropathology in PD /23/. The intravenous 
administration of Cop-I-stimulated spleen cells to 
MPTP-treated mice suppressed microglial activation 
and protected dopaminergic neurons. This reaction 
could be a direct effect of the immune cells as the 
injected cells were found in inflamed brain regions 
/6/. Depletion of the donor T cells abrogated the 
beneficial effects, indicating that this type of cell 
was responsible for the therapeutic benefit. 
Furthermore, the injection of regulatory T (Treg) 
cells, which can control the level of inflammation, 
protects against MPTP-induced dopaminergic 
neurodegeneration /61/, which is contradictory to a 
theory of protective autoimmunity /66/. 
Just as sera from healthy individuals contain 
anti-A13 auto-Abs, such sera also contain anti-a-
synuclein Abs. Whereas 31 % of control sera 
contain anti-a-synuclein Abs, 90% and 52% of 
sera from familial and sporadic PD patients, 
respectively, contain such Abs /54/. Because 
endogenous anti-a-synuclein Abs can be toxic or 
beneficial, their physiological effects must be 
determined. 
IMMUNIZATION THERAPIES FOR 
HUNTINGTON'S DISEASE 
Huntington's disease (HD) is an autosomal 
dominant, neurodegenerative disease resulting 
from the expansion of a normally occurring 
glutamine repeat in exon 1 of the huntingtin 
protein (Htt). When this expansion is greater than 
36, the protein misfolds and accumulates as 
aggregates /11,28/. The mutant Htt protein (mHtt) 
is deficient in performing vital functions of the 
wildtype Htt (wtHtt), including mediating axonal 
transport, transcriptional regulation, and mito-
chondrial metabolism. In addition, mHtt also 
engages in aberrant interactions, such as 
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sequestering important cellular proteins, including 
transcription factors and vesicle-associated 
proteins 129/. These interactions lead to striatal and 
corticaL atrophy as well as to motor and cognitive 
decline ISOI. Despite the simple genetic nature of 
lID, available therapies are aimed at symptom 
management rather than disease modification. 
Recent work has shown, however, that Ab-based 
therapeutic approaches can be developed against 
the most upstream target in HD, the mHtt protein 
itself. Such approaches have the potential to 
prevent the onset or delay the progression of lID. 
The intracellular localization of the mHtt 
protein makes it a less than ideal target for 
immunization therapies. Nonetheless, systemic 
vaccination with DNA for an N-terminal fragment 
of mHtt ameliorates the diabetic phenotype of the 
R6/2 transgenic mouse model of lID and 
normalizes pancreatic insulin levels 147/. This 
effect is reminiscent of the positive effects of 
peripheral injection of the cytoplasmic protein 
a-synuclein discussed above. The immunized 
mice, however, displayed highly variable serum 
responsiveness; no clear effects on brain pathology 
or behavior were observed, limiting the therapeutic 
potential of this approach. 
Intrabody therapy 
Intrabodies (iAbs), intracellularly expressed 
antibody fragments consisting only of antigen 
recognition domain(s), are a powerful potential 
therapeutic for proteinopathies, including AD, PD, 
and HD. These highly specific reagents can be 
developed to recognize an infinite number of 
targets, including amino acid sequence, protein 
conformation, post-translational modifications, and 
specific protein interactions. In addition, trafficking 
sequences can be used to target iAbs to specific 
sub-ceIL.dar compartments 144/. A number of 
therapeutic iAbs recognizing either distinct confor-
mations or distinct epitopes in proteins that cause 
neurodegenerative diseases have been developed. 
Conformation-specific intrabody therapies 
Each of the mutated proteins discussed here can 
. adopt a number of conformations, including 
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monomers, oIigomers, protofibrils, and the fibrillar 
structures found in A13 plaques, Lewy bodies, and 
large mHtt aggregates (Figure 1). Although some 
conformations confer toxicity, others perform the 
beneficial functions of these proteins. Amyloid 
precursor protein, which gives rise to A13, .. is 
involved in normal neuronal physiology, and 
perturbations could lead to unknown consequences. 
The a-synuclein protein is natively unfolded and 
although the oligomeric form is cytotoxic, the 
monomeric form performs vital beneficial functions. 
The mHtt protein is also a dynamic protein forming 
multiple structures. Targeting specific conforma-
tions of these disease-causing proteins with iAbs 
should allow therapeutic intervention with minimal 
disruption of normal function. Of note, a number of 
Abs have been isolated that bind well to oligomeric 
or fibrillar species of several different toxic proteins 
that do not share amino acid sequence homology 
18,311. Thus, these Abs apparently bind to a 
conformation shared by the amino acid backbone of 
several proteins, without regard to the diversity in 
amino acid side chains. 
DS is an iAb raised from a phage display 
library against oligomeric a-synuclein. This iAb 
reduces in vitro aggregation and extracellular 
toxicity of a-synuclein in neuroblastoma cells /161. 
When fused to a secretion signal (DS-SEC), this 
iAb causes the removal of intracellular 
a-synuclein, which in tum reduces the toxicity of 
overexpresssed a-synuclein in co-transfected 293 
cells 1811. DS also recognizes an oligomeric form 
of mHtt. Although it reduces aggregation of mHtt 
in vitro, DS binding increases toxicity in a cell 
culture model of HD IS1I. Another iAb, syn-lOH, 
recognizes a stage of a-synuclein oligomer that is 
larger and later than DS. This iAb recognizes 
aggregates in PD but not in normal human brain 
and reduces a-synuclein-induced toxicity in 
neuroblastoma cells 117/. 
6E is an iAb selected for binding to fibrillar 
a-synuclein but also recognizes only the fibrillar 
form of mHtt. This iAb increases fibril formation, 
aggregation, and toxicity of mHtt in a cell culture 
model of HD 1361. The extreme selectivity of 
conformation-specific iAbs that allow differentia-
tion, not only between mutant and wt proteins but 
also between various species of mutant proteins, 
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Monomer Oligomer Protoflbrll Fibril 
Fig. 1: Aggregating proteins adopt multiple conformations. Despite differences in size, sequence and function, the 
proteins that cause AD, PD and HD adopt similar structures including soluble monomers, small aggregated 
oliogomers, ~-sheet organized proto fibrils, and large aggregated cross-~-sheet amyloid fibrils. Molecular 
















Huntingtin exon 1 
rATLeKLMKAFESLKS~~QQQQQQQQ (vtPPPPPPPPPPQLPQPPPO:QPLLPQPQPPPPPPPPPPffAVAEEPlHRPK I 
t r , 
N1 .. 17 polyQ PRR C-term 
Fig. 2: Sequences and diagrams of several proteins that cause neurodegenerative disease. (A) Divergent proteolytic 
processing of APP leads either to production of the non-toxic P3 peptide or to the pr~duction of the pathogenic 
A~ peptide that accumulates in AD brain. (B) a-synuclein is the major protein co'mponent of the Lewy bodies 
characteristic of PD. The non-amyloid component (NAC) shown underlined is also found in the A~ plaques of 
AD. (C) Exon 1 of the Htt protein, the site of the mutation that causes HD. PRR, proline rich region. 
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warrants further investigation in both structural and 
therapeutic contexts. 
EPITOPE-SPECIFIC INTRABODY THERAPIES 
FOR ALZHEIMER'S DISEASE 
As discussed above, the major component of 
plaques in AD brains is AP, one of the products 
generated from the proteolytic processing of the 
amyloid precursor protein (APP). APP is processed 
by one of two mutually exclusive cleavage 
pathways. In the first, more common pathway, APP 
is cleaved by a-secretase generating the non-toxic 
P3 fragment. In the second much less common 
pathway, APP is cleaved by p-secretase generating 
AP (Figure 2A) /25/. The two common fonns of A~, 
are the 40 AA fonn, A~4o, and the 42 AA form, 
A~42' The longer form, A~42' is less soluble and has 
a greater propensity to fonn oligomers and fibrils, 
leading to enhanced toxicity /37/. 
As the differential proteolytic processing of 
APP can lead to either toxic or non-toxic products, 
emulating or enhancing the a-secretase cleavage of 
APP has therapeutic potential. A screen of iAbs for 
a-secretase-like activity identified two iAbs with 
possible therapeutic applications for AD. A serine-
protease-like iAb, c23.5, mimics a-secretase 
cleavage, producing the 1-16 and 17-40 amino acid 
fragments of A~. A carboxypeptidase-like iAb, 
hkl4, sequentially cleaves the C-tenninal residues 
of A~42' generating the less toxic A~4o /59/. Another 
iAb, sFv~l, recognizes an epitope adjacent to the a-
secretase site of APP at AA 3-6 of A~. This iAb 
shifts APP processing toward the more favorable a-
secretase product, reducing A~ production and 
toxicity in co-transfected 293 cells. When fused to 
an endoplasmic reticulum (ER) retention signal, 
sFv~ I prevents the newly generated APP from 
leaving the ER, leading to its degradation and 
virtually abolishing A~ production /53/. 
Other iAbs have been selected from phage 
display libraries for A~-binding efficacy. HI v2 is 
an iAb that recognizes AA 17-28 of A~ and 
reduces its in vitro aggregation. The co-incubation 
of this iAb with A~ prevents extracellular toxicity 
to neuroblastoma cells /43/. The adeno-associated 
virus (AA V)-mediated delivery of anti-A~ iAb 
scFv59 to the cortico-hippocampal region of the 
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brains of Tg2576 AD model mice results in strong 
iAb expression and reduced A~ plaque load as 
long as I year post-injection 1211. 
Immunization studies have identified mono-
clonal Abs that when passively delivered, prevent 
A~ plaque deposition in the brains of AD trans-
genic mice. Three iAbs have been generated from 
such Abs; scFv9, which recognizes AA 1-16 and 
binds both A~40 and A~42, and scFv40.1 and 
scFv42.2, which respectively recognize A~40 and 
A~42, /42/. An AA V -mediated delivery of any of 
these iAbs to the ventricles of PO CRND8 AD 
model mice resulted in a 25% to 50% reduction in 
A~ plaque deposition 1411. The beneficial effects 
of scFv42.2 were enhanced by the addition of an 
ER retention signal. The AA V -mediated delivery 
of the modified iAb to the hippocampus of 3xTg-
AD model mice resulted in not only reduced A~42 
plaque load but also reduced levels of hyper-
phosphorylated tau, once again indicating that tau 
pathology is downstream of the A~ pathology in 
AD 174/. 
EPITOPE-SPECIFIC INTRABODY THERAPIES 
FOR PARKINSON'S DISEASE 
The primary component of the Lewy body 
inclusions that characterize PD is a-synuclein, and a 
portion of this protein, the non-amyloid component 
(NAC), is found in AD plaques (Figure 2B). 
Although far less common than sporadic PD, 
familial PD is most often caused by mutations in the 
a-synuclein gene. Moreover, the overexpression of 
wt a-synuclein is sufficient to cause a PD-like 
toxicity in cells, flies, and mice 112/. For these 
reasons, a-synuclein is the primary therapeutic iAb 
target for PD. 
NAC32 is an iAb selected from a phage-
display library against the NAC of a-synuclein. 
NAC32 expression reduces the aggregation and 
toxicity of a mutant form of a-synuclein in co-
transfected STl4A cells /45/. Another iAb selected 
from a phage display library is DIO, which 
recognizes monomeric a-synuclein. D I 0 expression 
reduces the aggregation and toxicity of over-
expressed wt a-synuclein in co-transfected 293 
cells. When fused to a nuclear localization signal 
(NLS), this iAb re-targets a-synuclein to the 
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nucleus, but has no effect on the localization of the 
highly homologous a-synuclein, demonstrating the 
extreme specificity of iAbs /82/. The beneficial 
effects on toxicity are augmented when DIO is 
fused to a secretion signal (D 1 O-SEC), leading to 
the removal of a-synuclein from cells /81/. 
Interestingly D 1 O-SEC leads to the removal of 
larger quantities of a-synuclein than the oligomer-
specific D5-SEC, but is not as beneficial, 
indicating lower cellular levels of the more toxic 
oligomeric species. 
EPITOPE-SPECIFIC INTRABODY THERAPIES 
FOR HUNTINGTON'S DISEASE 
Exon 1 ofHtt (HDx-I), the site of the mutation 
that cal'.ses HD, consists of 17 N-terminal amino 
acids, a polyglutamine (polyQ) tract, the proline 
rich region (PRR) that includes two polyproline 
(polyp) tracts separated by a proline rich (P-rich) 
sequence, and 13 C-terminal amino acids (Fig. 
2C). Potential therapeutic iAbs recognizing each of 
the four regions ofHDx-1 have been developed. 
Intrabodies recognizing Nl-l7 
The N-terminus of Htt is the site of many 
important interactions including membrane 
association and post-translational modifications /4, 
62/. This domain regulates the localization, 
aggregation and degradation of Htt /76,77/. Two 
iAbs recognizing this region, C4 and Vd2.3, have 
been developed as potential therapeutics. 
C4 is an iAb isolated from a phage-display 
library that preferentially binds to diffuse but not to 
aggregated N-terminal Htt fragments /48/. The 
expression of this iAb in 293 and ST14A cells 
reduces the level of both wt and aggregated mHtt, 
but increases the level of soluble mHtt /48/. The 
C4 iAb was originally shown to reduce the 
aggregation and toxicity of mHtt in cell culture 
models ofHD, but it required a 5:1 ratio to mHDx-
1 for optimal effects /39/. Re-engineering C4, 
which involved mutagenizing and selecting for 
greater Htt binding affinity, resulted in an iAb that 
protects against malonate-induced toxicity in 
mHDx -1-transfected organotypic slice cultures 
/49/. In a Drosophila model of HD, the C4 iAb 
also rescues the eclosion deficit, increases adult 
survival, and decreases photoreceptor degeneration 
/80/. 
VL I2.3 is a single domain, light chain iAb 
selected from a yeast surface display library that 
reduces mHDx-l aggregation in a cell-free system 
as well as in mHtt co-transfected 293 cells /9/. 
Although originally requiring a 5: 1 ratio to mHDx-l 
for optimum effects, the VL I2.3 iAb was re-
engineered by removal of the disulfide bond, 
random mutagenesis and selection for greater Htt 
binding affinity, yielding a very stable, soluble and 
potent iAb /10/. The mature Vd2.3 iAb reduces 
mHDx-l- induced toxicity and aggregation at low 
iAb:HDx-l ratios in both cell culture and 
organotypic slice culture models ofHD. Consistent 
with the cytoplasmic retention function of the Htt 
N-terminus, VL I2.3 binding also causes an 
increase in nuclear HDx-l /71/. The Vd2.3 iAb 
was also tested in vivo in a variety of mouse 
models of HD. In one model involving the 
lentiviral delivery of mHDx-l to the striatum of 4-
week-old wt mice, the AAV-mediated striatal 
delivery of VL I2.3 dramatically reduces mHtt 
aggregation and striatal neuron death and rescues 
the abnormal amphetamine-induced rotation 
phenotype of these mice. Despite such promising 
results in acute cellular and in vivo models of HD, 
the AA V-V d 2.3 treatment of R6/2 and transgenic 
models of HD results in no change or even a 
worsening of phenotypic severity, including 
decreased survival of R6/2 mice despite a dramatic 
reduction in striatal HDx-l aggregates /72/. 
The target of C4 and VL12.3, the N-terminus 
of Htt, is required for cytoplasmic retention. 
Compromising the cytoplasmic retention this 
function of the Htt N-terminus results in increased 
nuclear Htt that is associated with increased 
toxicity /56,62/. The N-terminus domain is also 
required for aggregate seeding, which may be a 
protective mechanism /2,67,7576/. The N-terminus 
is also the site of several important post-
translational modifications, including phosphory-
lation, which increases the degradation of mHtt 
and is neuro-protective /24,76,77/. For these 
reasons, the iAb blockade of the N-terminus ofHtt 
may not be an ideal long-term therapeutic strategy 
for HD, as suggested by in vivo results with 
VL12.3. 
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Intrabodies recognizing polyQ 
The expanded polyQ tract is the only AA 
sequence difference between wt and mHtt, and as 
the polyQ tract alone ,can confer toxicity, this 
epitope should be an ideal target for iAb therapy 
directed selectively at mHtt. 
MW 1 and MW2 are iAbs derived from 
monoclonal antibodies that recognize polyQ in 
HDx-l. The iAbs preferentially bind mHDx-l and 
mHtt and recognize both the native and denatured 
proteins. Despite the ability of the expanded polyQ 
domain to confer toxicity, the treatment of cell 
culture and organotypic brain slice models of lID 
with MWI or MW2 increases mHDx-l-induced 
toxicity and aggregation 133/. This increase in 
toxicity could potentially be the result of an iAb-
mediated stabilization of a toxic conformation of 
mHDx-l or an iAb-mediated cross-linking of 
mHDx-l molecules, which could accelerate 
oligomer formation. An exploration of such possible 
mechanisms may shed light on the molecular basis 
of mHtt toxicity. Despite the potential selectivity of 
targeting this domain, the results indicate that iAb 
binding to the polyQ tract is more likely to 
potentiate than to ameliorate toxicity. 
Intrabodies recognizing the proline rich region 
The PRR of mHtt mediates a number of 
aberrant protein-protein interactions, including the 
sequestration of SH3 and WW domain-containing 
transcription factors and vesicle proteins 118,58/. 
These domains are the site of interactions with 
IKKy, a regulatory subunit of the IKE kinase 
complex. Activating this complex promotes 
aggregation and nuclear localization of mHtt 134/. 
The PRR of Htt is also the site of its interactions 
with P53 and the CREB-binding protein and the 
PRR is required for mHtt-induced transcriptional 
repression of P53-regulated genes /73/. All these 
toxic interactions are strengthened in response to 
increased polyQ length. Three iAbs recognizing 
the PRR domain, MW7, Happl and Happ3, have 
been developed as possible HD therapeutics. 
MW7 is an iAb derived from a monoclonal 
antibody that recognizes polyP. This iAb reduces 
mHDx -1-induced toxicity and aggregation in cell 
culture, Drosophila, and organotypic brain slice 
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models of HD 130,33,711. MW7 binding results in 
an increased clearance of soluble mutant but not 
wtHDx-l, a mechanism with great therapeutic 
potential /71/. The MW7 iAb is, however, not very 
potent as it requires a 4: 1 ratio to mHDx-l for 
optimal effects 133/. Although no evidence of 
MW7 binding to proteins other than Htt has been 
observed, the specificity of this iAb for pure polyP 
could potentially allow binding to other polyP 
domain-containing proteins. 
Happ 1 and Happ3 are single domain V L iAbs 
selected from a phage-display library that 
recognize the P-rich domain of Htt lying. between 
the two polyP tracts (Fig. 2C). These iAbs have the 
beneficial properties of MW7, including the 
reduction of mHtt-induced aggregation and 
toxicity in cell culture and organotypic brain slice 
models of HD, as well as an increased clearance of 
mHtt. Moreover, the recognition of a single, 
unique sequence found only in Htt increases the 
likelihood of extreme binding specificity. In 
addition, Happ 1 and 3 display increased potency 
over MW7, requiring a 2: 1 ratio to mHtt for 
optimum effects /711. Although these iAbs bind to 
both mutant and wtHDx-l in denaturing conditions, 
the selectivity for the increased clearance of only 
the mutant protein in cells in native conditions 
indicates a strong preference for this form. This 
preference may be due to the increased availability 
of the PRR epitope in expanded polyQ Htt 
conformations. This idea is supported by the 
findings of increased binding of other Htt PRR-
interacting partners with increased polyQ length 
155,58,73/. 
The results obtained with five different HD 
mouse models further support the therapeutic 
utility of Happ 1 172/. AA V ~mediated intrastriatal 
delivery of this iAb in the lentiviral mouse model 
dramatically reduces mHDx-l aggregation and 
striatal neuron death and completely rescues the 
amphetamine~induced rotation behavioral phenol-
type. In addition, delivery of AAV-Happl to the 
striatum of the R6/2, NI71-82Q, YAC128, and 
BACHD transgenic HD models ameliorates many 
aspects of the HD-like phenotype. Normal motor 
performance is restored in N171-82Q, YAC128, 
and BACHD mice, and motor performance is 
improved in R6/2 mice. The cognitive effects of 
mHtt are another important aspect of HD, and 
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GFP treated HD mouse Happ1 treated HD mouse 
Fig. 3: Happi treatment improves body weight ofNI7I-82Q HD model mice. The OFP-treated NI7I-82Q mouse (left) 
oisplays reduced body weight, crouched posture and ruffled coat, whereas the Happ I-treated NI7I-82Q mouse 
(right) displays normal body weight and appearance. The mice shown are male littermates. 1721 
Happ 1 treatment restores normal cognitive 
performance in YACl28 mice and improves 
cognitive performance in BACHD mice. Happ 1 
treatment also ameliorates neuropathology in these 
models. HDx-1 aggregation is strongly reduced in 
the R6/2 model, and ventricle size is normalized in 
R6/2, YACI28, and BACHD mice. Although 
Happl has no effect on R6/2, YAC128, or 
BACHD body weight or R6/2 survival, this iAb 
does significantly increase both body weight and 
life span of N171-82Q mice (Figure.3) /72/. 
Engineering to increase stability and binding 
affinity could potentially further improve this very 
promising iAb. 
One potential mechanism that could mediate 
the positive effects of the anti-PRR iAbs could 
involve the blockade of a number of aberrant 
interactions of mHtt with other proteins that lead to 
a gain of toxic function. Another mechanism 
involves the regulation of mHtt stability because 
iAb binding to the PRR leads to increased clearance 
of the mutant but not the wildtype protein. 
Intrabodies recognizing the C terminus ofHDx-l 
Although the functions of the C-terminus of 
HDx-1 are unclear, results with two iAbs, EM48 
and MW8, which bind this region, indicate that this 
domain contributes to mHtt toxicity. 
EM48 is an iAb derived from a monoclonal 
antibody that recognizes an epitope in the C-
terminus of HDx-l that is adjacent to the PRR. 
This iAb preferentially binds mHDx-1 and increases 
its ubiquitination and turnover in a cell-culture 
model of HD. Adenoviral delivery of EM48 to the 
striatum of R6/2 and N171-82Q HD model mice 
reduces striatal neuropil aggregates, increases Htt 
cleavage products, and improves the motor 
performance of N171-82Q mice. Yet, EM48 gene 
therapy has no effect on intranuclear inclusions, 
body weight, or survival /79/. 
MW8 is an iAb derived from a monoclonal 
antibody that recognizes a unique epitope in the C-
terminus of HDx':'l. This iAb preferentially binds 
aggregated rather than diffuse Htt, allowing 
selectivity for the mutant form. MW8 treatment 
reduces mHtt-induced toxicity and aggregation in 
cell culture models of HD, although its beneficial 
effects are modest in comparison to those of 
several other iAbs, making MW8 a poor choice for 
further development /35/. 
Taken together, these studies demonstrate that 
the iAb gene therapy strategy for the treatment of 
HD can be very effective. Those iAbs directed at 
the regions flanking the HD mutation rather than at 
the mutation itself, and particularly those that can 
distinguish between mutant and wtHtt, display the 
greatest promise. 
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PERSPECTIVES 
Clearly, a wide variety of antibody-based 
therapies can have striking efficacy in animal 
models of AD, PD, and HD. Clinical testing of 
passive and active AI) immunization for AD is 
quite advanced. Regrettably, the early safety 
results nave been somewhat mixed, and the early 
efficacy results have certainly not been as 
impressive as in the mouse models. Nonetheless, 
this therapy is still in its very early days, and one 
should recall the many missteps and the fine-
tuning that was required to achieve the nearly 
uniform success we now enjoy with bone marrow, 
kidney, and heart transplant procedures. Many 
patients gave their lives in those clinical 
experiments, which has not yet been the case in the 
context of immunotherapy for AD, PD, and HD. 
Indeed, more than fine-tuning must be done to test 
immunctherapy for neurodegenerative diseases. 
Clinical experiments are needed to sort out the 
relative efficacy of non-specific versus highly 
specific antibody approaches, systemic versus 
intracranial delivery, gene therapy versus active or 
passive immunization, and antibody versus 
intrabody approaches. Hopefully, the large clinical 
trials of immunization for AD now underway will 
yield enough positive results to sustain the 
momentum . of the immunotherapy approach to 
these devastating diseases. 
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